RxDoctor Payments Data

Brian Murrell, PA

Physician Assistant · Monroe, GANPI 1063694859

Payments from drug & device makers

$10,022in general payments, 2019–2025

Across 474 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Novo Nordisk$1K
  • Sanofi-aventis U.S. LLC$913
  • Lilly USA, LLC$800
  • Dexcom, Inc.$595
  • Amgen$389
  • plus $4K from 41 others

What the payments were for

  • Food & beverage$10,011100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,022 in reported general payments places this provider in the 95th percentile of 3,581 physician assistant providers in Georgia.

See all physician assistant providers in Georgia

Medicare billing

Part B allowed, 2024
$6,371
Medicare patients
70
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide357$635,527
JardianceEmpagliflozin176$244,439
MounjaroTirzepatide127$227,202
TrulicityDulaglutide90$164,288
Tresiba Flextouch U-100Insulin Degludec131$159,676
Tresiba Flextouch U-200Insulin Degludec44$123,471
JanuviaSitagliptin Phosphate83$112,469
FarxigaDapagliflozin Propanediol94$108,588
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog43$78,445
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog50$58,408
Lantus SolostarInsulin Glargine,hum.Rec.Anlog173$41,316
Novolog FlexpenInsulin Aspart117$40,334
RybelsusSemaglutide19$39,908
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog44$39,219
Fiasp FlextouchInsulin Aspart (Niacinamide)34$35,861

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,350$682,302400 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi$800$410,813256 claims
Boehringer IngelheimJardiance$135$244,439176 claims
AstraZenecaFarxiga$359$108,58894 claims
AbbVieSynthroid$194$7,56272 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$117$3,326292 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,581 physician assistant providers in Georgia.

Other physician assistant in Monroe

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →